Research Roundup


old bulbs with a smart bulb in middle

Debbie Rigby takes a look at the latest in research news

Cannabis for paediatric epilepsy: challenges and conundrums

Evidence for its efficacy in treating epilepsy is limited but growing, with a single pharmaceutical company-funded randomised double-blind controlled trial in children with Dravet syndrome. The mechanism of cannabidiol in paediatric epilepsy is unclear but is thought to play a role in modulation of synaptic transmission.

Med J Aust 2018; 208 (3): 132-136.

 

Psychotropic prescribing in Australian residential aged care

A cross-sectional, retrospective cohort study of residents from 150 Australian  residential aged care facilities has shown that regular antipsychotic use appears to have decreased in residential aged care facilities during April 2014–October 2015, but benzodiazepine prevalence is higher, particularly in South Australian residential aged care facilities. Sedating antidepressant and ‘prn’ psychotropic prescribing is widespread. The researchers concluded that effective interventions to reduce the continued reliance on psychotropic management, in conjunction with active promotion of non-pharmacological strategies, are urgently required.

Australian & New Zealand Journal of Psychiatry, 2018.

 

Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey

A survey to measure the level of anticoagulation knowledge in patients with AF taking oral anticoagulants (OACs) identified knowledge gaps in patients taking OACs, and these deficiencies appeared to be greater in participants taking DOACs. The authors conclude that knowledge assessment should be integrated into patient counselling sessions to help identify and resolve knowledge deficits.

Int J Clin Pract. 2018;e13072.

 

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty

An RCT (EPCAT 11) of 3424 patients undergoing total hip or knee replacement has shown 5 days of rivaroxaban 10mg followed by aspirin 81mg once daily was not significantly different during a 90-day follow-up from rivaroxaban 10mg therapy in the prevention of symptomatic venous thromboembolism (VTE). There was no significance difference in clinically important bleeding events.

N Engl J Med 2018;378:699-707.

Medscape comment

Previous Pharmacists to tackle aged care overmedication
Next Drugs' hidden side effects

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.